Thoughts on "When Breath Becomes Air"

Article

A cancer survivor faces a fear and reads the book, "When Breath Becomes Air."

Over the summer, a friend asked if I read Dr. Paul Kalanithi’s memoir, “When Breath Becomes Air.” I had not, but decided to look it up and was immediately flooded with anxiety. The story is 35-year-old neurosurgeon diagnosed with advanced stage lung cancer’s thoughts on life and dying. Deciding the book was too close to home, I added it to my list of 2017 fear-conquering goals. Only the book wouldn’t go away and appeared on my Amazon recommendations and in the front section of every bookstore I entered. I conceded and purchased it because I felt like the universe was telling me to I needed to read this book. I’m glad I did.

Before getting into the major takeaways, it should be acknowledged from a writing standpoint, Dr. Kalanithi “spun gold.” He strung his story together with complexity, elegance and creativity and it’s no doubt he found his true callings by being both a writer and a doctor.

In terms of his disease, I feel that being a physician was a blessing and a curse. Obviously, he was knowledgeable to the medical and scientific aspects, often to a fault.

“I began to suspect that being so close to the fiery light of such moments only blinded me to their nature.” He knew enough to ask his oncologist the Kaplan-Meier survival rates and his oncologist knew enough not to answer, but that he would look them up on his own. Eventually, Kalanithi realized, “detailed statistics are made for research halls, not hospital rooms,” a philosophy I wished more doctors adopted.

At the debut of his illness, he appeared to struggle and eventually come to grips with the emotional, mental and spiritual aspects of disease. I’ve come to learn these are some of the biggest oversights by our doctors. Call me naive, but I’m a firm believer in positivity and faith, and I think Dr. Kalanithi discounted these aspects early on, but eventually confronted them when he said, “Science may provide the most useful way to organize empirical, reproducible data, but its power to do so is predicted on it’s inability to grasp the most central aspects of human life: hope, fear, love, hate, beauty, envy, honor, weakness, striving, suffering, virtue.

Between these core passions and scientific theory, there will always be a gap. No system of thought can contain the fullness of the human experience.”

I think “When Breath Becomes Air” should be annual reading for doctors, if only to have both a peer’s and patient’s insight into illness. Dr. Kalanithi explained, “How little do doctors understand the hells through which we put patients.” Also, to reaffirm, “Doctors invade the body in every way imaginable. They see people at their most vulnerable, their most scared, their most private. They escort them into the world, and then back out. Seeing the body as matter and mechanism is the flip side to easing the most profound human suffering.”

Throughout the book, there were many relatable moments. Early on when Dr. Kalanithi said, “Severe illness wasn’t life-altering, it was life-shattering,” and “Even when the cancer was in retreat, it cast long shadows.”

And the most relatable theme for me personally - the biggest fear not being death, but leaving a spouse alone and “promising her one life and giving her another.”

Unfortunately, Paul Kalanithi passed away while writing this book, but in my eyes, it’s actually quite complete. His widow wrote the epilogue and beautifully summarized their journey through illness. “Although these last few years have been wrenching and difficult — sometimes almost impossible —they have also been the most beautiful and profound of my life, requiring the daily act of holding life and death, joy and pain in balance and exploring new depths of gratitude and love.”

Now, if you haven’t read, “When Breath Becomes Air,” go out and buy two copies — one for you, and one for your oncologist.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL